DDInter212 DDInter1658
Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Bisacodyl {u} (Compound) resembles {v} (Compound) Carbinoxamine
Bisacodyl {u} (Compound) resembles {v} (Compound) Dexbrompheniramine
Bisacodyl {u} (Compound) binds {v} (Gene) GPR55
Bisacodyl {u} (Compound) upregulates {v} (Gene) KTN1
Bisacodyl {u} (Compound) is included by {v} (Pharmacologic Class) Stimulation Large Intestine Fluid/Electrolyte Secretion
Bisacodyl {u} (Compound) downregulates {v} (Gene) MTMR4
Bisacodyl {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Bisacodyl {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Bisacodyl (Compound) resembles Dexbrompheniramine (Compound)
Bisacodyl (Compound) binds GPR55 (Gene)
Bisacodyl (Compound) upregulates KTN1 (Gene)
Bisacodyl (Compound) is included by Stimulation Large Intestine Fluid/Electrolyte Secretion (Pharmacologic Class)
Bisacodyl (Compound) downregulates MTMR4 (Gene)
Bisacodyl (Compound) causes Nervous system disorder (Side Effect)
Bisacodyl may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant